Biovie Inc. (NASDAQ: BIVI)

Biovie Inc., a clinical-stage company operating in the pharmaceutical industry, is dedicated to the development of innovative drug therapies for the treatment of neurological and neurodegenerative disorders, as well as advanced liver disease. The company's main business activities revolve around researching, developing, and bringing to market groundbreaking therapies that address significant unmet medical needs. Biovie operates primarily in the United States, with a strong presence in the neurological and liver disease therapeutic areas.

The company generates revenue primarily through the development of its two primary products, NE3107 and BIV201. NE3107 is a potentially selective inhibitor of inflammatory ERK signaling, being developed for the treatment of Alzheimer's disease (AD) and Parkinson's disease (PD). Biovie is currently conducting a Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients with mild to moderate AD. The study has co-primary endpoints looking at cognition and function using the Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). NE3107 has also shown promising results in a Phase 2 study for PD patients, with patients treated with NE3107 experiencing greater motor control and improvements in non-motor symptoms.

BIV201, on the other hand, is an orphan drug candidate being developed for the treatment of ascites due to chronic liver cirrhosis. Biovie has completed a Phase 2 study, which showed a 34% reduction in ascites fluid during the 28 days after treatment initiation compared to the 28 days prior to treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in ascites fluid, which was sustained during the three months after treatment initiation. The company has filed a Patent Cooperation Treaty (PCT) application covering its novel liquid formulations of terlipressin and plans to seek patent protection in at least the U.S., Europe, China, Japan, and other jurisdictions.

Biovie's position within the industry is strong, with a focus on developing innovative therapies for neurological and neurodegenerative disorders and advanced liver disease. The company's competitive advantages include its proprietary novel liquid formulation of terlipressin, which has room temperature stability and is designed to improve convenience for outpatient administration. Key competitors within the neurological and liver disease therapeutic areas include companies such as Pfizer, Merck, and Gilead Sciences.

The company's customers are patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. The FDA has granted Fast-Track status and Orphan Drug designation for the most common complication, ascites, which represents a significant unmet medical need.